Haleraid is a non-powered device designed to help patients with impaired hand agility (e.g. due to arthritis, muscle weakness) administer aerosol medication from a metered dose inhaler (MDI). It is in the form of a plastic housing within which the MDI is placed, and which facilitates the manual actuation of the MDI, using leverage. Haleraid is a device developed to help patients with impaired hand agility administer GSK’s Seretide (salmeterol xinafoate /fluticasone propionate), Serevent (salmeterol), Flixotide (fluticasone Propionate) and Ventolin (salbutamol) 200 and 120 dose Evohalers. This is a reusable device.
Discontinuation of Haleraid globally
This is a reusable device and patients can continue to use the Haleraid devices that they have as normal. For any alternatives, patients should discuss these with their healthcare provider.
[Haleraid] is a registered trademark of the GlaxoSmithKline group of companies